Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention
Top Cited Papers
Open Access
- 16 July 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 140 (3), 240-261
- https://doi.org/10.1161/circulationaha.119.040167
Abstract
Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of standardization in defining this population limits trial design, data interpretation, and clinical decision-making. The Academic Research Consortium for High Bleeding Risk (ARC-HBR) is a collaboration among leading research organizations, regulatory authorities, and physician-scientists from the United States, Asia, and Europe focusing on percutaneous coronary intervention-related bleeding. Two meetings of the 31-member consortium were held in Washington, DC, in April 2018 and in Paris, France, in October 2018. These meetings were organized by the Cardiovascular European Research Center on behalf of the ARC-HBR group and included representatives of the US Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, as well as observers from the pharmaceutical and medical device industries. A consensus definition of patients at high bleeding risk was developed that was based on review of the available evidence. The definition is intended to provide consistency in defining this population for clinical trials and to complement clinical decision-making and regulatory review. The proposed ARC-HBR consensus document represents the first pragmatic approach to a consistent definition of high bleeding risk in clinical trials evaluating the safety and effectiveness of devices and drug regimens for patients undergoing percutaneous coronary intervention.This publication has 140 references indexed in Scilit:
- Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary StentingThe New England Journal of Medicine, 2012
- Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary StentingCirculation, 2012
- Atherothrombosis in von Willebrand Disease: An Analysis of the Literature and Implications for Clinical ManagementSeminars in Thrombosis and Hemostasis, 2012
- In-Hospital Major Bleeding During ST-Elevation and Non–ST-Elevation Myocardial Infarction Care: Derivation and Validation of a Model from the ACTION Registry®-GWTG™The American Journal of Cardiology, 2011
- Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trialAmerican Heart Journal, 2011
- Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary StentsThe New England Journal of Medicine, 2010
- Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosisEuropean Heart Journal, 2010
- Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent StrokeThe New England Journal of Medicine, 2008
- A model to predict survival in patients with end-stage liver diseaseHepatology, 2001
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000